Literature DB >> 16010981

Regulation of high molecular weight bovine brain neutral protease by phospholipids in vitro.

V Chauhan1, A M Sheikh, A Chauhan, W D Spivack, M D Fenko, M N Malik.   

Abstract

The activity of the heat stable, glycosylated high molecular weight bovine brain neutral protease (HMW protease) is differentially regulated by phospholipids. While phosphatidylcholine (PC), phosphatidylserine (PS) and phosphatidic acid (PA) had only marginal stimulatory effect (40-75%) on the activity of HMW protease, lysophoshatidylcholine (lysoPC) and lysophosphatidic acid (lysoPA) activated the enzyme by more than two-fold. Both lysoPC and lysoPA exhibited concentration-dependent saturation kinetics for the activation of HMW protease. Surprisingly, phosphoinositides (phosphatidylinositol, PI; phosphatidylinositol 4-phosphate, PIP; and phosphatidylinositol 4,5-bisphosphate, PIP2) modulated the activity of protease differently: activation of the enzyme was higher with PIP (90%) as compared to PI (21%), whereas PIP2 inhibited the enzyme (16%). The inhibition of the protease by PIP2 was concentration-dependent. During receptor-coupled cell activation, phospholipase A2 (PLA2) converts PC and PA to lysoPC and lysoPA, respectively; PI is converted to PIP2 by successive enzymatic phosphorylation by PI 4-kinase and PIP 5-kinase; and phospholipase C (PLC) degrades PIP2 to diacylglycerol and inositol 1,4,5-trisphosphate. Therefore, the data suggest that HMW protease may be coupled to cell signal transduction where PLA2, PI 4-kinase, PIP 5-kinase and PLC are involved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010981     DOI: 10.1007/s11010-005-6915-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  34 in total

Review 1.  Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome.

Authors:  K D Wilkinson
Journal:  Semin Cell Dev Biol       Date:  2000-06       Impact factor: 7.727

Review 2.  Signal peptidases in prokaryotes and eukaryotes--a new protease family.

Authors:  R E Dalbey; G Von Heijne
Journal:  Trends Biochem Sci       Date:  1992-11       Impact factor: 13.807

3.  Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells.

Authors:  D A Fishman; Y Liu; S M Ellerbroek; M S Stack
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

4.  Immunocytochemical localization of the high molecular weight protease in brain.

Authors:  M N Malik; M D Fenko; A M Sheikh; G Y Wen; H M Wisniewski
Journal:  Brain Res       Date:  1994-11-14       Impact factor: 3.252

5.  Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells.

Authors:  N Inoue; S Takeshita; D Gao; T Ishida; S Kawashima; H Akita; R Tawa; H Sakurai; M Yokoyama
Journal:  Atherosclerosis       Date:  2001-03       Impact factor: 5.162

6.  Extracellular release of the glycosylphosphatidylinositol (GPI)-linked Leishmania surface metalloprotease, gp63, is independent of GPI phospholipolysis: implications for parasite virulence.

Authors:  Bradford S McGwire; William A O'Connell; Kwang-Poo Chang; David M Engman
Journal:  J Biol Chem       Date:  2002-01-02       Impact factor: 5.157

7.  Phosphoinositide-specific inositol polyphosphate 5-phosphatase IV inhibits Akt/protein kinase B phosphorylation and leads to apoptotic cell death.

Authors:  Marina V Kisseleva; Li Cao; Philip W Majerus
Journal:  J Biol Chem       Date:  2001-11-12       Impact factor: 5.157

8.  Free fatty acids inhibit the activity of Clostridium histolyticum collagenase and human neutrophil elastase.

Authors:  Beate Rennert; Matthias F Melzig
Journal:  Planta Med       Date:  2002-09       Impact factor: 3.352

Review 9.  The proprotein convertases.

Authors:  D F Steiner
Journal:  Curr Opin Chem Biol       Date:  1998-02       Impact factor: 8.822

Review 10.  A review of the proteasome inhibitor bortezomib in multiple myeloma.

Authors:  Paul G Richardson
Journal:  Expert Opin Pharmacother       Date:  2004-06       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.